Years published: 1991, 1995, 1996, 1998, 2006, 2011, 2014, 2017, 2020
NORD gratefully acknowledges Joshua W. Knowles, MD, PhD, Attending Physician, Stanford Center for Inherited Cardiovascular Disease and Chief Medical Advisor, The FH Foundation, Hannah Wand, MS, LCGC, Genetic Counselor, Stanford Center for Inherited Cardiovascular Disease, and Hannah Ison, MS, LCGC, Genetic Counselor, Stanford Center for Inherited Cardiovascular Disease, for assistance in the preparation of this report.
Familial hypercholesterolemia (FH) is a diagnosis which refers to individuals with very significantly elevated low-density lipoprotein (LDL) cholesterol (LDL-C) or “bad cholesterol” and an increased risk of early onset of coronary artery disease if not sufficiently treated. Most commonly, individuals have heterozygous familial hypercholesterolemia (HeFH), caused by a single DNA variant (alteration) for FH that they have inherited from one (affected) parent. In rare cases, an individual can have homozygous familial hypercholesterolemia (HoFH), caused by having two causal FH DNA variants, where one variant is inherited from each (affected) parent. Individuals with HoFH typically have a more severe form of disease. For the purposes of this report, “FH” will refer to HeFH unless otherwise stated.
FH is one of the most common genetic diseases and affects approximately 1 in 250 individuals. Several standardized criteria have been developed to diagnose FH, including the Dutch Lipid Clinic Network, Simon Broome, and MEDPED diagnostic criteria. A diagnosis of FH can be made using any criteria. When evaluating someone for FH, it is important to rule out secondary causes of elevated LDL-C. If DNA testing is performed on an individual meeting clinical criteria for FH, most will be found to have a pathogenic variant in one of three relevant genes (LDLR, APOB, and PCSK9).
In 20-30% of individuals that meet clinical criteria for FH, standard clinical genetic testing may be negative in individuals due to reasons such as technical limitations (e.g. clinical sensitivity of current technology) or causal genes not yet discovered. Therefore, a negative FH genetic test result does not rule out a diagnosis of FH, but may lower the suspicion for FH in circumstances where a diagnosis of FH is unclear. There is emerging data for alternative genetic causes for a clinical FH presentation, including a very high polygenic burden (see Related Disorders section) that should be considered.
Having FH greatly increases the risk of hardening of the arteries (atherosclerosis), which can lead to heart attacks, strokes and other vascular conditions. Untreated individuals with FH have a 20-fold increased risk for coronary artery disease (CAD). Untreated men have a 50% risk of a nonfatal or fatal heart attack (coronary artery blockage) by age 50 years; untreated women have a 30% risk by age 60 years. If one or more other risk factors for CAD are present, especially cigarette smoking or diabetes mellitus, the risk of developing symptomatic CAD is even higher.
FH is treatable and the associated cardiovascular disease is largely preventable with early and intensive treatment, using statins, additional drugs, and other means. Other non-statin medications include PCSK9 inhibitors, ezetimibe, and bempedoic acid. These are effective treatments for individuals with FH who have a persistently elevated LDL-C despite treatment with maximally tolerated statin therapy.
Early identification and treatment of individuals with FH is key to preventing cardiovascular disease. Underdiagnosis of FH is a problem in most countries as high cholesterol can be an invisible and undetected problem until it leads to coronary artery disease. When an individual with FH is identified, it is important to identify other affected family members through “cascade screening” or “family screening.” Family members who have not yet exhibited cardiovascular symptoms and who are appropriately treated are likely to live a normal lifespan. Without proper family screening, family members will have undetected very high cholesterol and are at risk to develop early onset CAD. It is common for individuals with FH to have a strong family history of premature CAD (men < 60 years, women <50 years) and sudden cardiac death. With improved detection and preventative treatment, the prevalence of premature CAD in families is declining.
HoFH is very rare (~ 1 in 250,000). LDL-C levels are usually, though not always, > 400 mg/dl. Severe vascular disease including CAD and aortic stenosis are often seen by the teenage years. Without very aggressive treatment including LDL-C apheresis and HoFH specific medications, mortality is common before age 30.
In 1973, Joseph Goldstein and Michael Brown identified and characterized a cell membrane protein they called the LDL receptor and the variation in the low-density lipoprotein receptor gene (LDLR) that interfered with its function. Normally functioning receptors lower the blood levels of LDL-C by taking up the lipoproteins that carry LDL-C in the liver. Pathogenic variants in this gene cause a decrease either in the number or function of the receptors, resulting in the extreme LDL-C elevations seen in FH. Goldstein and Brown became the first investigators to identify a variation that caused a metabolic disorder when only a single abnormal gene was present. In 1985 they won the Nobel Prize in Medicine for this work. Their pioneering work and the subsequent studies of LDL-C metabolism in FH patients greatly contributed to our knowledge about the link between cholesterol and heart disease and led to the development of numerous therapeutic agents that benefit a very large number of individuals with high cholesterol. Since that time, other genes causing FH such as the apolipoprotein B-100 gene (APOB) and the proprotein convertase subtilisin/kexin type 9 gene (PCSK9) have been identified (see below). Importantly, there is a great deal of evidence showing that early diagnosis and intensive treatment can prevent illness and death due to FH.
Heterozygous Familial Hypercholesterolemia
People with FH have very high levels of LDL-C from birth. In children, LDL-C levels are usually > 160 mg/dl, but can be lower, and in adults LDL-C is usually > 190 mg/dL. This very high LDL-C level is toxic to the body and causes atherosclerosis in the arteries over time. For individuals with FH, the exposure to elevated LDL-C begins at birth. When untreated, this can lead to premature CAD, cerebrovascular disease, peripheral vascular disease and/or other serious conditions.
Most common is CAD due to atherosclerotic plaque build-up in the arteries supplying the heart (atherosclerosis), which can result in chest pain or discomfort (angina), heart attack (myocardial infarction) or sudden death. Untreated people with FH have an approximately 10 to 20-fold increased risk for CAD. It is estimated that 1 in 10 individuals with a heart attack at a young age (<50) have FH, and this may be as high as 6 in 10 if there is a family history of CAD and the LDL-C is > 160 mg/dl at the time of the heart attack.
Less common are cerebrovascular disease, peripheral vascular disease and aortic aneurysm. Cerebrovascular disease may occur due to cholesterol build-up in the arteries supplying the brain, which may cause stroke or transient ischemic attack (TIA).
Peripheral vascular disease is due to cholesterol build-up in the arteries supplying the legs which may cause pain when walking that is relieved by rest (claudication) and at its most severe, pain at rest or critical lack of blood flow.
Extravascular clinical features of FH
Xanthomas are firm nodules caused by cholesterol buildup as a result of the very high levels of LDL-C. The most common sites are the Achilles tendon and the tendons on top of the hands (less common). Achilles tendon xanthomas may cause tendonitis, an inflammation of the tendon that may tear or rupture. Tendon xanthomas are seen in <15% of individuals with HeFH in the current era and in a much higher percentage of those with HoFH. Xanthesmas are cholesterol deposits on, above or under the eyelids can be seen in ~5% of patients with FH. They may also be seen in individuals with normal cholesterol levels, particularly as they age. Corneal arcus is a white, grey or blue opaque ring around the edge of the cornea in the eye, can be seen in ~30% of patients with FH. Since corneal arcus is common in African Americans with normal cholesterol levels and becomes increasingly common in the general population with age, it is only useful as a diagnostic tool in younger individuals, particularly in those under age 45.
Of note, children with heterozygous FH are less likely to present with these physical exam findings. Additionally, the longer an individual is treated with statins, the less likely these extra-vascular findings will be present.
Homozygous Familial Hypercholesterolemia
Individuals with HoFH exhibit extremely high LDL-C levels, usually above 400 mg/dL. They usually have xanthomas by early childhood. Planar xanthomas affecting the skin on the hands, elbows, buttocks and knees in a young child are diagnostic for this condition. Corneal arcus surrounding the entire inside edge of the cornea is often present. Most individuals with HoFH experience severe CAD by their mid-20’s if not aggressively treated. Narrowing of the heart valve leading to the aorta (aortic stenosis) often occurs, which may make it necessary to replace the aortic valve. Very aggressive therapy is needed to reduce the likelihood of vascular events. Most affected people will require filtering of their blood (LDL apheresis) and/or medications specifically approved by the FDA for HoFH (lomitapide, PCSK9 inhibitors or mipomersen).
Often the other medications that are the mainstay of treatment for HeFH (such as statins) are relatively ineffective in HoFH. This is because the mechanism of action of statins normally “triggers” the liver to express additional LDL receptors. In the most severe cases of HoFH, the LDL receptors are completely inactive which makes this response futile. Statins can be effective in individuals with HoFH if there is some residual LDL-R activity, or if they have causal DNA variants in the APOB or PCSK9 genes.
Genetics of FH
HeFH occurs when a child inherits a nonfunctional copy of one of their FH genes (LDLR, APOB, PCSK9) from an affected parent and a functional copy from their unaffected parent. Each egg or sperm they produce has a 50% chance of getting the nonfunctional copy (passing down FH) and a 50% chance of getting the functional copy, Therefore, the risk of passing the FH from the affected parent to a child is 50% in each pregnancy. New, spontaneous variants appear to be very rare.
Most individuals with HoFH have inherited one mutated gene from each parent, such that each parent has HeFH. These parents have a 25% risk in each pregnancy to have a child with HoFH, a 50% chance of having a child with HeFH, and a 25% chance that the child will inherit a normal gene from each parent. The risk is the same for males and females.
When one parent has HeFH and the other has HoFH, there is a 50% chance with each pregnancy to have a child with HeFH and a 50% chance to have a child with HoFH.
When one parent has HoFH and the other has two normal genes, all children will have HeFH.
When both parents have HoFH, all children will have HoFH.
In FH there is a “dose effect” so that HoFH is more severe than HeFH.
Variation by gene
Of patients with identifiable pathogenic gene variants, a LDLR gene variant is the most common cause of HeFH, accounting for ~90% of pathogenic variants. Since the original pathogenic variant discovered by Goldstein and Brown, over 2500 other variants in the same gene have been identified. An adequate number of functioning LDL receptors are needed to remove cholesterol from the bloodstream.
A pathogenic variant in the APOB gene is responsible for ~10% of FH cases; this variation is seen most commonly in those of European Caucasian ancestry. It is also associated with lower baseline LDL-C levels compared to most cases of FH, closer to 160 mg/dl. Apolipoprotein B-100 is a protein that binds to LDL receptors, which enables uptake of lipoproteins by the liver and reduces the cholesterol level in the blood. Pathogenic variants in the APOB gene lead to faulty uptake and increased cholesterol level.
PCSK9 gene variants are responsible for only a small percentage of FH cases. The normal PCSK9 gene codes for an enzyme that breaks down the cholesterol receptors after they have done their job. Unlike most pathogenic variants which cause a loss of function of the affected gene, PCSK9 pathogenic variants actually increase the gene’s function. This gain in function in PCSK9 leads to excess degradation of LDL receptors and thus an increase in the LDL-C levels.
Recent research suggests individuals with FH that have variants in different genes (LDLR, APOB, PCSK9) or of different types of DNA changes may have different individual risks. However, there is wide enough variation even among those data sets and it can be difficult to provide personalized risk information by one’s genotype.
FH due to a change in LDLR, APOB or PCSK9 is referred to as a monogenic disease, where a change in any one of those genes is sufficient to cause disease. In contrast, there is growing evidence to show that some individuals with a clinical FH presentation (defined by any of the standard diagnostic criteria signs and symptoms) actually have a polygenic predisposition to hyperlipidemia as an alternative genetic cause to their disease. Polygenic disease is due to changes in many genes, often broadly related to cholesterol metabolism. The contribution of any single genetic change is very small and it takes the combination of these many, changed genes to get significantly elevated LDL-C. Polygenic hyperlipidemia can present as severe as FH, but can often also present milder or more variable than monogenic FH because the number of changes inherited by any one family member is always different. Polygenic hyperlipidemia is described in more detail in the “Related Disorders” section.
Recent studies have shown that FH is as common as 1 in 250, making it one of the most common genetic diseases. However, most individuals go undiagnosed and most are undertreated given their very high risk. Small subpopulations around the world have a higher incidence, such as Lebanese Christians (1/85), Afrikaners in South Africa (1/72 – 1/100), French Canadians (1/270), and Ashkenazi Jews originating from Lithuania (1/67) known as a founder effect.
The frequency of HoFH across populations is estimated to be 1 in 1/160,000 to 1 250,000. HoFH is more likely to occur in countries where the prevalence of HeFH is very high, especially those where consanguinity (marriage between relatives) is common.
FH should be considered in an untreated child with LDL-C above 160 mg/dL, or with LDL-C above 130 mg/dL and a positive family history of FH or premature heart disease. In untreated adults, an LDL-C above 190 mg/dL, a personal and/or family history of early CAD, physical signs such as those described under “Symptoms, or a relative known to have FH, should increase the suspicion of FH
FH can be diagnosed using DNA testing or by utilizing one of three well-accepted sets of criteria — Simon Broome (UK), Dutch Lipid Clinic Network (Netherlands), or MEDPED (US). Of note, the Dutch Lipid Clinic Network criteria are unable to be used in the pediatric setting. In individuals suspected to have “definite” FH based on clinical criteria, an FH variant is identified approximately 60-80% of the time. In individuals with “possible” FH based on clinical criteria, an FH variant is identified approximately 20-40% of the time. DNA testing confirms the diagnosis and is considered the “gold standard”, but is not always necessary or feasible. DNA testing should definitely be considered when it’s not clear whether an individual is affected or not, and is very helpful for testing family members. Recent studies also suggest that individual risks for CAD vary among the affected gene and type of DNA variation (substitution vs. partial deletion of a gene, etc.). Individuals with an LDL-C >190 mg/dL and a FH pathogenic variant have been noted to have a 10 fold increased relative risk for CAD (compared to the general population) while those with an LDL-C >190 mg/dL and no FH pathogenic mutation have a 3-fold increased relative risk for CAD (compared to the general population). Therefore, individuals who test positive on genetic testing may infer an increased risk of CAD over an individual with negative genetic testing at any given LDL-C level.
Once an individual is diagnosed with FH (either with or without the use of DNA testing) a process called “cascade screening”, “cascade testing” or “family screening” (testing of close relatives, in a step-wise fashion) is recommended to identify those with FH before symptoms appear, so that early and intensive treatment can be initiated and disease and death prevented. If a pathogenic variant is identified, risk in the patient’s first degree relatives (parent, sibling, child) and when appropriate, more distant relatives, can be accessed via DNA testing by tracing the altered gene through the family. If DNA testing is not performed, another version of cascade screening can be implemented using cholesterol testing. Cascade screening by either means has been shown to be effective in finding patients with FH who were not being appropriately treated. A genetic counselor can help a family through this process. (http://www.nsgc.org/page/find-a-gc-search )
Cascade screening has been shown in numerous studies to be cost-effective and has been recommended by the National Institute for Health and Clinical Excellence (NICE) in the UK. The Office of Public Health Genomics at the Centers for Disease Control and Prevention considers cascade screening of relatives of those with FH a “Tier 1 application” which means that there is good evidence that implementation will prevent disease and save lives.
HoFH is easily identified in infants and young children by the presence of planar xanthomas, corneal arcus, and exceedingly high total and LDL-C; LDL-C is usually greater than 400 mg/dL. The parents are “obligate heterozygotes” who are considered to have HeFH until proven otherwise.
Clinical Testing and Workup
Evaluations following initial diagnosis
To establish the extent of disease and needs of an individual diagnosed with FH, the following evaluations are recommended in adults and children:
• Pre-treatment lipid values
• Lipoprotein(a) levels when possible as lipoprotein(a) is an additional risk factor for CAD
• Exclusion of concurrent illnesses (kidney disease,uncontrolled hypothyroidism, acute myocardial infarction, infection) that can affect lipid values
• Lipid panel including total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and triglycerides
• Consultation with a lipid specialist or clinician with expertise in FH
• Medical genetics or a genetic counseling consultation
In children, noninvasive imaging modalities (e.g., measurement of carotid intima-media thickness) are recommended in some guidelines to help inform treatment decisions.
Treatment of FH is focused on reducing the LDL-C levels in order to decrease the risk for atherosclerotic heart disease.
Adults with FH
Dietary changes such as restricting saturated fat and eliminating trans-fats have significant cholesterol-lowering impact. Decreasing dietary cholesterol and increasing soluble fiber are also helpful. The diet should primarily be made up of vegetables, whole fruit and grains, nuts and legumes. Seafood, lean poultry and low fat dairy products are the preferred sources of animal protein. Weight loss and aerobic exercise have modest effects on cholesterol level but can help to lower blood pressure and blood sugar levels and thus cardiovascular disease risk.
Cholesterol lowering medication
For adults, treatment should begin as soon as possible after diagnosis. Almost all will require cholesterol-lowering drug therapy. A firm diagnosis of FH should prompt more aggressive treatment than would otherwise be undertaken in a patient with “garden variety” high cholesterol. Some guidelines state that the untreated cholesterol level should be reduced by at least 50%; others suggest that less than 100 mg/dL is the goal for individuals without a prior CVD event. LDL-C goals are more stringent (typically <70 mg/dl) when additional risk factors such as diabetes or atherosclerosis are present. Patients with FH should be referred to a lipidologist if these goals cannot be reached in the primary care setting.
Pharmacotherapy should initially be statin-based, followed by addition of other drugs if the targeted LDL-C level is not achieved with statins and lifestyle changes. Preference should be given to one of the higher potency statins (atorvastatin or rosuvastatin) used at the maximal dose.
Muscle injury (rhabdomyolysis) is the major risk of statins but is very rare, seen in approximately 1/10,000 of those taking these drugs. Damage to the liver does not occur at a higher rate than in people not taking a statin. However, myalgia (muscle pain) is a relatively common side effect occurring in 10-15% of patients. Mild myalgia with or without mild creatine kinase elevations (less than 5 times the upper limit of normal) are not necessarily a reason to discontinue statins or other cholesterol lowering medications.
Other drugs such as ezetimibe (Zetia), bile acid sequestrants (colesevelam, Welcol), bempedoic acid (Nexletol) and icosapent ethyl (Vascepa), or PCSK9 inhibitors (evolocumab; Repatha or alirocumab; Praluent) (approved in 2015 for the treatment of HeFH and HoFH) may be necessary.
In patients who cannot achieve the desired LDL-C level, a procedure called LDL apheresis (similar to dialysis for kidney disease) may be necessary.
Children with HeFH
Parents should discuss with the pediatrician when to initiate treatment in a child with FH. Treatment should be considered when LDL-C level is greater than 190 mg/dl, or greater than 160 md/dl with at least two other risk factors present. The National Lipid Association guidelines recommend referral to a lipid specialist, management of diet and physical activity from an early age, and consideration of statin treatment. Atorvastatin and rosuvastatin, two of the stronger statins, are approved for use in children by the Federal Drug Administration, as are all of the weaker statins. The goal is at least a 50% reduction in LDL-C or LDL-C below 130 mg/dL. Statins can be initiated as early as 8 to 10 years old; adverse effects of statins in childhood have not been reported. Studies have shown that children who begin statins have a statistically significant decreased risk of developing coronary artery disease compared to their parents affected with FH. The goal of initiating statins in childhood is to reduce the cumulative lifetime burden of exposure to LDL-C levels.
Children or Adults with HoFH
Early initiation of therapy and monitoring using CT coronary angiography and other imaging are recommended; these patients often require additional treatment strategies, as pharmacological treatment and lifestyle changes may not be sufficient. Statins are usually started as soon as the diagnosis is made (though may not be effective as explained above). Lomitapide is now a FDA-approved treatment for adults with HoFH and should be considered for these patients, especially if LDL-C level cannot be controlled using other drugs. A PCSK9 inhibitor, evolocumab, was also approved by the FDA for HoFH. In 2021, the FDA approved evinacumab-dgnb (Evkeeza) injection as an add-on treatment for patients aged 12 and older with HoFH and in 2023 approval was expanded to children aged 5-11. Additional options include LDL apheresis or liver transplantation.
Using a process similar to kidney dialysis, blood is withdrawn from a vein via a catheter and processed to remove LDL-C particles. Normal blood products are returned via another catheter. LDL-C levels will decrease approximately 50% but will rise between apheresis sessions, so they are necessary approximately weekly or every other week. The procedure is effective and well tolerated though time-consuming and only available in 50-60 sites in the US.
Liver transplant is extraordinarily rare and may become even less common with the new medications available. As the donor liver will have normal LDL receptors, the LDL-C quickly normalizes after the procedure, but the risks of any organ transplant are significant and include complications from major surgery and the effects of lifelong suppression of the immune system. Donor organs are often not available. Patients with familial pathogenic APOB or PCSK9 gene variants have normal LDL receptors, so liver transplantation is not an option for them.
Various imaging modalities such as echocardiograms, CT angiograms and cardiac catheterization may be recommended to monitor individuals with HoFH.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government website.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Toll-free: (800) 411-1222
TTY: (866) 411-1010
Email: [email protected]
Some current clinical trials also are posted on the following page on the NORD website:
For information about clinical trials sponsored by private sources, in the main, contact:
For more information about clinical trials conducted in Europe, contact:
Fahed AC, et al. Risk of myocardial infarction in carriers of familial hypercholesterolemia mutations is modified by common variant genetic background or adherence to a healthy lifestyle. Circulation 2019; 140.Suppl 1: A15044-A15044.
Luirink IK, et al. 20-Year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med 2019; 381:1547-1556.
Sarraju A and Knowles JW. Genetic testing and risk scores: impact on familial hypercholesterolemia. Frontiers in Cardiovascular Medicine 2019; 6: 5.
Singh A, et al. Familial hypercholesterolemia among young adults with myocardial infarction.” Journal of the American College of Cardiology 2019; 73.19: 2439-2450.
Sturm AC, et al. Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel. Journal of the American College of Cardiology 2018; 72.6: 662-680.
Abul-Husn NS, et al. Genetic identification of familial hypercholesterolemia within a single US health care system. Science 2016; 354.6319: aaf7000.
Degoma EM, et al. Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-FH registry. Circulation: Cardiovascular Genetics 2016; 9.3:240-249.
Khera AV, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. Journal of the American College of Cardiology 2016; 67.22: 2578-2589.
Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015 Sep 21;36(36):2425-37. doi: 10.1093/eurheartj/ehv157. Epub 2015 May 25.
Knowles JW, O’Brien EC, Greendale K, et al. Reducing the burden of disease and death from familial hypercholesterolemia: A call to action. Am Heart J. 2014 Dec;168(6):807-11. doi: 10.1016/j.ahj.2014.09.001. Epub 2014 Sep 16.
Sturm, AC. The role of genetic counselors for patients with familial hypercholesterolemia. Curr Genet Med Rep. 2014;2: 68-74.
Raal FJ and Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223:262-8.
Blom, DJ. Familial hypercholesterolaemia. S Afr Fam Pract. 2011;53(1):11-18.
Goldberg AC, Hopkins PN, Toth PP, et al. Executive Summary. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients. J Clin Lipidology. 2011;5:133-40.
Kwiterovich PO Jr. Clinical implications of the molecular basis of familial hypercholesterolemia and other inherited dyslipidemias. Circulation. 2011;123:1153-1155.
Ned RM and Sijbrands EJ. Cascade screening for familial hypercholesterolemia (FH). PloS Curr. 2011;3:RRN 1238.
Lughetti l, Bruzzi P, Predieri B. Evaluation and management of hyperlipidemia in children and adolescents. Curr Opin Pediatr. 2010;22:485-93.
McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, Hayman LL, Daniels SR. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007;115:1948-1967.
Expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.
Goldstein JL, Brown MS. The Cholesterol Quartet. Science. 2001;292 (5520):1310-1312.
Youngblom E, Pariani M, Knowles JW. Familial Hypercholesterolemia. 2014 Jan 2 [Updated 2016 Dec 8]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK174884/ Accessed May 20, 2020.
Learn Your Lipids – Patient information from the Foundation of the National Lipid Association. http://www.learnyourlipids.com/ Accessed May 20, 2020.
Kindt I, O’Brien EC, Marquess M, Greendale K, Wilemon K and Knowles JW Proceedings of the Familial Hypercholesterolemia Foundation’s Inaugural Familial Hypercholesterolemia Summit: Awareness to Action. March 17, 2014. https://thefhfoundation.org/proceedings-fh-foundations-inaugural-familial-hypercholesterolemia-summit-awareness-action Accessed May 20, 2020.
Medline Plus – U.S. National Library of Medicine, National Institutes of Health. Familial Hypercholesterolemia.5/16/2018. https://medlineplus.gov/ency/article/000392.htm Accessed May 20, 2020.
NORD strives to open new assistance programs as funding allows. If we don’t have a program for you now, please continue to check back with us.
NORD and MedicAlert Foundation have teamed up on a new program to provide protection to rare disease patients in emergency situations.Learn more https://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/
Ensuring that patients and caregivers are armed with the tools they need to live their best lives while managing their rare condition is a vital part of NORD’s mission.Learn more https://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/
This first-of-its-kind assistance program is designed for caregivers of a child or adult diagnosed with a rare disorder.Learn more https://rarediseases.org/patient-assistance-programs/caregiver-respite/